子宫颈腺癌预后因素的临床分析及苦参相关制剂干预对其预后的作用

发布时间：2018-04-13 09:15

本文选题：子宫颈腺癌 + 预后因素　；参考：《辽宁中医药大学》2017年硕士论文

【摘要】：目的:分析可能影响子宫颈腺癌预后的相关因素,讨论中药苦参相关制剂辅助治疗对子宫颈腺癌预后的影响,为子宫颈腺癌患者的预后及中西医治疗提供理论依据。材料与方法:回顾性分析2014年1月至2016年12月于辽宁省肿瘤医院妇科住院治疗的178例经病理诊断为子宫颈腺癌的患者,其中拒绝治疗5例,共173例被纳入研究。按病例纳入标准搜集患者的相关临床资料。使用SPSS17.0统计软件对收集的资料进行分析和处理,使用寿命表法分别算出其1年、2年和3年生存率,影响子宫颈腺癌预后的相关因素分析使用Kaplan-Meier法,并用Log-rank进行差异性检验,多因素分析采用Cox回归模型进行数据处理。P0.05认为差异有统计学意义。结果:1.纳入研究的子宫颈腺癌患者复发率为2.31%,转移率为9.83%。1年生存率为91%,2年生存率为76%,3年生存率为73%。2.临床分期、肌层浸润程度和有无淋巴结受累是子宫颈腺癌预后的相关影响因素(P0.05),临床分期和有无淋巴结受累是其独立的预后影响因素(P0.05)。3.子宫颈腺癌的FIGO分期中,I期的3年生存率为92%、II期的3年生存率为74%、III期的3年生存率为36%,3年总生存率为81%。4.是否使用中药苦参相关制剂辅助治疗不是子宫颈腺癌预后的相关影响因素(P0.05),但从生存率可以看出,使用中药苦参相关制剂辅助治疗的子宫颈腺癌患者的生存质量情况明显优于未使用的。结论:1.临床分期、肌层浸润程度和有无淋巴结受累是子宫颈腺癌预后的相关影响因素,且临床分期和有无淋巴结受累是其独立的预后影响因素。2.采用中药苦参相关制剂辅助治疗不是子宫颈腺癌预后的相关影响因素,但可以提高子宫颈腺癌患者的生存率,改善预后。
[Abstract]:Objective: to analyze the related factors that may affect the prognosis of cervical adenocarcinoma, and discuss the influence of the auxiliary therapy of traditional Chinese medicine Sophora flavescens on the prognosis of cervical adenocarcinoma, so as to provide a theoretical basis for the prognosis of cervical adenocarcinoma patients and the treatment of traditional Chinese medicine and western medicine.Materials and methods: 178 cases of cervical adenocarcinoma diagnosed by pathology from January 2014 to December 2016 in Liaoning Cancer Hospital were retrospectively analyzed. Among them, 5 cases were refused treatment and 173 cases were included in the study.Collect the relevant clinical data according to the standard of case inclusion.The data collected were analyzed and processed by SPSS17.0 software. The 1 year, 2 year and 3 year survival rates were calculated by using life table method. Kaplan-Meier method was used to analyze the related factors affecting the prognosis of cervical adenocarcinoma and Log-rank was used to test the difference.Multivariate analysis using Cox regression model for data processing. P05 that the difference was statistically significant.The result is 1: 1.The recurrence rate was 2.31, the metastasis rate was 9.83.1 year survival rate was 91, the 2-year survival rate was 76, and the 3-year survival rate was 73.2.Clinical stage, myometrial invasion degree and lymph node involvement were related factors of prognosis of cervical adenocarcinoma. Clinical stage and lymph node involvement were independent prognostic factors.In FIGO staging of cervical adenocarcinoma, the 3-year survival rate of stage I was 92and the 3-year survival rate of stage II was 74.The 3-year survival rate of stage III was 36, and the overall survival rate of 3-year was 81.4.Whether or not to use the traditional Chinese medicine Sophora flavescens associated with adjuvant treatment is not a related factor for the prognosis of cervical adenocarcinoma P0.05, but from the survival rate can be seen,The quality of life (QOL) of patients with cervical adenocarcinoma treated with Sophora flavescens was significantly better than that of untreated patients.Conclusion 1.The clinical stage, the degree of myometrial invasion and lymph node involvement were related factors of prognosis of cervical adenocarcinoma, and clinical stage and lymph node involvement were independent prognostic factors.The adjuvant therapy of Sophora flavescens is not a related factor in the prognosis of cervical adenocarcinoma, but it can improve the survival rate and prognosis of patients with cervical adenocarcinoma.
【学位授予单位】：辽宁中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.33

【参考文献】